MX2017009003A - Preparados combinados para el tratamiento contra el cancer o infecciones. - Google Patents

Preparados combinados para el tratamiento contra el cancer o infecciones.

Info

Publication number
MX2017009003A
MX2017009003A MX2017009003A MX2017009003A MX2017009003A MX 2017009003 A MX2017009003 A MX 2017009003A MX 2017009003 A MX2017009003 A MX 2017009003A MX 2017009003 A MX2017009003 A MX 2017009003A MX 2017009003 A MX2017009003 A MX 2017009003A
Authority
MX
Mexico
Prior art keywords
infection
cancer
treatment
combined preparations
lag
Prior art date
Application number
MX2017009003A
Other languages
English (en)
Inventor
Brignone Chrystelle
Triebel Frédéric
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immutep Sas filed Critical Immutep Sas
Publication of MX2017009003A publication Critical patent/MX2017009003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Se describen los preparados combinados y composiciones farmacéuticas que comprenden: (a) proteína LAG-3, o un derivado de la misma que sea capaz de unirse a moléculas del CPH tipo II y (b) un inhibidor de la vía de proteína-1 de muerte celular programada (PD-1). El inhibidor de la vía PD-1, tal como un anticuerpo anti-PD-1 o un anticuerpo anti-PD-L1 y un derivado soluble de LAG-3 actuando como activador de APC, juntos activan sinérgicamente los linfocitos T (especialmente a los linfocitos T CD8+). Se describe el uso de preparados combinados y composiciones a manera de medicamentos, en particular para el tratamiento contra el cáncer o infecciones, y métodos para el tratamiento contra el cáncer o infecciones.
MX2017009003A 2015-01-09 2016-01-08 Preparados combinados para el tratamiento contra el cancer o infecciones. MX2017009003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500374.2A GB201500374D0 (en) 2015-01-09 2015-01-09 Combined preparations for the treatment of cancer
PCT/EP2016/050321 WO2016110593A1 (en) 2015-01-09 2016-01-08 Combined preparations for the treatment of cancer or infection

Publications (1)

Publication Number Publication Date
MX2017009003A true MX2017009003A (es) 2018-03-15

Family

ID=52597438

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000299A MX2021000299A (es) 2015-01-09 2016-01-08 Preparados combinados para el tratamiento contra el cancer o infecciones.
MX2017009003A MX2017009003A (es) 2015-01-09 2016-01-08 Preparados combinados para el tratamiento contra el cancer o infecciones.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000299A MX2021000299A (es) 2015-01-09 2016-01-08 Preparados combinados para el tratamiento contra el cancer o infecciones.

Country Status (22)

Country Link
US (5) US10874713B2 (es)
EP (3) EP3473263B1 (es)
JP (4) JP7116547B2 (es)
KR (1) KR20170120104A (es)
CN (2) CN107249619B (es)
AU (3) AU2016205983B2 (es)
BR (1) BR112017014742A2 (es)
CA (1) CA2973044A1 (es)
CY (1) CY1124462T1 (es)
DK (2) DK3473263T3 (es)
ES (2) ES2704272T3 (es)
GB (1) GB201500374D0 (es)
HR (1) HRP20211346T1 (es)
HU (1) HUE055433T2 (es)
IL (1) IL253243A0 (es)
LT (1) LT3473263T (es)
MX (2) MX2021000299A (es)
PL (2) PL3473263T3 (es)
PT (2) PT3242678T (es)
SI (1) SI3473263T1 (es)
TR (1) TR201901077T4 (es)
WO (1) WO2016110593A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
DK3081576T3 (da) 2013-12-12 2019-10-21 Shanghai hengrui pharmaceutical co ltd Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
CN110720039A (zh) 2017-05-30 2020-01-21 百时美施贵宝公司 Lag-3阳性肿瘤的治疗
EP3768727A4 (en) * 2018-03-20 2021-12-22 Wuxi Biologics Ireland Limited. NEW BIS SPECIFIC PD-1 / LAG-3 ANTIBODY MOLECULES
CA3107660A1 (en) * 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
EP3972607A4 (en) * 2019-05-22 2023-08-16 Agency for Science, Technology and Research PHARMACEUTICAL COMBINATION
EP3982983A4 (en) * 2019-06-14 2023-11-15 G Tech Bio LLC ACTIVATED LYMPHOCYTES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
CN110938691B (zh) * 2019-12-03 2023-07-07 兰州大学 人dus4l基因的用途及相关产品
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
GB202108718D0 (en) 2021-06-18 2021-08-04 Immutep Sas Triple combination therapy

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
NZ232562A (en) 1989-02-17 1992-10-28 Coselco Mimotopes Pty Ltd Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
US7294712B2 (en) 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ATE129746T1 (de) 1990-09-14 1995-11-15 Univ Johns Hopkins Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
JP3459268B2 (ja) 1990-09-17 2003-10-20 中外製薬株式会社 抗癌剤
ATE504650T1 (de) 1991-02-08 2011-04-15 Aventis Pharma Sa Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
JPH06502997A (ja) 1991-02-12 1994-04-07 ルセル　ユクラフ ヒトＴリンパ球レセプターのβ鎖の可変領域をコードするヌクレオチド配列対応するペプチドセグメント並びに診断及び治療への利用
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US6506604B2 (en) 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
KR100257466B1 (ko) 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
ATE320488T1 (de) 1996-11-28 2006-04-15 Roussy Inst Gustave Mutanten des lag-3 proteins, ihre expression und verwendung
CA2272130C (en) 1996-11-29 2007-10-23 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6037177A (en) 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ATE264911T1 (de) 1998-02-02 2004-05-15 Univ Johns Hopkins Med Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
WO2000072686A1 (en) 1999-06-02 2000-12-07 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
WO2000077201A1 (en) 1999-06-15 2000-12-21 Astrazeneca Ab Livin; inhibitor-of-apoptosis protein-3 (iap-3)
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
AT409086B (de) 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
WO2001080836A1 (fr) 2000-04-26 2001-11-01 Biovector Therapeutics Utilisation de vecteurs particulaires dans l'immunomodulation
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
CN1697655B (zh) 2002-05-17 2013-09-18 细胞基因公司 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物
JP4409430B2 (ja) 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CN1889963A (zh) 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
JP2006124383A (ja) 2004-09-30 2006-05-18 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
JP2006141346A (ja) 2004-11-24 2006-06-08 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20070231298A1 (en) 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2648734B1 (en) 2010-12-06 2019-02-13 Cure Cancer Worldwide LLC Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
KR102289394B1 (ko) 2011-03-31 2021-08-13 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
IN2014KN00848A (es) * 2012-02-01 2015-10-02 Compugen Ltd
CA2873402C (en) * 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
EP3508502B1 (en) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015131176A1 (en) 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Also Published As

Publication number Publication date
TR201901077T4 (tr) 2019-02-21
JP7116547B2 (ja) 2022-08-10
ES2704272T3 (es) 2019-03-15
SI3473263T1 (sl) 2022-01-31
CA2973044A1 (en) 2016-07-14
PT3473263T (pt) 2021-08-26
BR112017014742A2 (pt) 2018-02-06
HUE055433T2 (hu) 2021-11-29
US20230330182A1 (en) 2023-10-19
DK3473263T3 (da) 2021-09-06
PL3473263T3 (pl) 2021-12-13
US20230074746A1 (en) 2023-03-09
RU2017127000A (ru) 2019-02-11
CN107249619B (zh) 2021-10-29
GB201500374D0 (en) 2015-02-25
JP2022118119A (ja) 2022-08-12
RU2017127000A3 (es) 2019-07-30
EP3242678B1 (en) 2018-11-28
EP3242678A1 (en) 2017-11-15
PT3242678T (pt) 2019-02-04
AU2022200133A1 (en) 2022-02-10
AU2024204196A1 (en) 2024-07-11
JP2020073594A (ja) 2020-05-14
US20200121757A1 (en) 2020-04-23
US20180271940A1 (en) 2018-09-27
CN107249619A (zh) 2017-10-13
US10874713B2 (en) 2020-12-29
JP2018506520A (ja) 2018-03-08
DK3242678T3 (en) 2019-03-11
JP2024015265A (ja) 2024-02-01
WO2016110593A1 (en) 2016-07-14
US10940181B2 (en) 2021-03-09
CN114146161A (zh) 2022-03-08
PL3242678T3 (pl) 2019-05-31
AU2016205983A1 (en) 2017-08-03
KR20170120104A (ko) 2017-10-30
AU2016205983B2 (en) 2021-10-28
EP3473263B1 (en) 2021-06-02
EP3943099A1 (en) 2022-01-26
EP3473263A1 (en) 2019-04-24
ES2885901T3 (es) 2021-12-15
US20210177937A1 (en) 2021-06-17
CY1124462T1 (el) 2021-12-31
MX2021000299A (es) 2021-10-26
LT3473263T (lt) 2021-09-27
US11684654B2 (en) 2023-06-27
IL253243A0 (en) 2017-08-31
HRP20211346T1 (hr) 2021-11-26

Similar Documents

Publication Publication Date Title
MX2017009003A (es) Preparados combinados para el tratamiento contra el cancer o infecciones.
WO2019222112A8 (en) Mcl-1 inhibitors
EP4230627A3 (en) Inhibitors of the menin-mll interaction
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
MY197324A (en) Adenovirus armed with bispecific t cell activator
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
PH12017500803A1 (en) Anti-pd-1 antibodies
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MY176235A (en) Compounds that inhibit mcl-1 protein
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2019036031A3 (en) Immunotherapeutic tumor treatment method
MX2018009247A (es) Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.
CY1122689T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
BR112017018198A2 (pt) inibição da atividade de olig2
CL2018002136A1 (es) Combinaciones de dihidrocloruro de histamina y uso de estas
MX2021009189A (es) Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
CL2011000645A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; y composicion farmaceutica que los comprende; y su uso en eltratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).